INCYIncyte CorporationRunning, no new patients
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
B-Cell Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 112 (final count)
- Started
- Aug 3, 2020
- Main results expected
- Nov 5, 2026
- Fully finished
- Nov 5, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measured over: Through study completion, an average of 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04509700 · record last updated 2026-06-25 · checked 2026-11-09 15:47 UTC